West Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major West syndrome markets reached a value of US$ 205.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 310.3 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.
The West syndrome market has been comprehensively analyzed in IMARC's new report titled "West Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". West syndrome, also known as infantile spasms, refers to a rare type of epilepsy that typically develops in infants under the age of one. The condition is characterized by a specific type of seizure called spasms, which are brief, involuntary muscle contractions that can cause the body to jerk or twitch. Infants suffering from this ailment may experience developmental delays, intellectual disability, and psychomotor retardation. Other common symptoms associated with West syndrome include crankiness, loss of appetite, changes in sleep patterns, regression, etc. The diagnosis of this disease is based on a review of the patient's medical history, clinical features, and neurological examination. An electroencephalogram (EEG) is also utilized among patients to detect patterns of electrical activity in the brain. The healthcare provider may further perform numerous diagnostic tests and procedures, including magnetic resonance imaging, computed tomography scan, urinalysis, cerebrospinal fluid test, blood workup, etc., to confirm a diagnosis and rule out other possible causes for underlying indications.
The rising cases of metabolic disorders, which can lead to a deficiency in brain energy, resulting in uncontrolled electrical abnormalities and brain damage, are primarily driving the West syndrome market. In addition to this, the increasing prevalence of various associated risk factors, such as brain injury, genetic defect, infection, brain malfunction, etc., is also acting as another significant growth-inducing factor. Furthermore, the widespread adoption of effective medications, including adrenocorticotropic hormone, prednisone, vigabatrin, pyridoxine, etc., to treat epileptic spasms and provide symptom relief in infants suffering from West syndrome, is creating a positive outlook for the market. Besides this, the emerging popularity of vagus nerve stimulation therapy, which helps to reduce seizures, promote mental development, and improve the quality of life of the patients, is also bolstering the market growth. Moreover, the escalating demand for a diet involving high fat, low carbohydrate with an adequate amount of protein and nutrients to control spasms, stabilize EEG, and enhance development and cognition, is expected to drive the West syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the West syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for West syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the West syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the West syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the West syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current West syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the West syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the West syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the West syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of West syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of West syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of West syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with West syndrome across the seven major markets?
What is the size of the West syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of West syndrome?
What will be the growth rate of patients across the seven major markets?
West Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for West syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the West syndrome market?
What are the key regulatory events related to the West syndrome market?
What is the structure of clinical trial landscape by status related to the West syndrome market?
What is the structure of clinical trial landscape by phase related to the West syndrome market?
What is the structure of clinical trial landscape by route of administration related to the West syndrome market?
The West syndrome market has been comprehensively analyzed in IMARC's new report titled "West Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". West syndrome, also known as infantile spasms, refers to a rare type of epilepsy that typically develops in infants under the age of one. The condition is characterized by a specific type of seizure called spasms, which are brief, involuntary muscle contractions that can cause the body to jerk or twitch. Infants suffering from this ailment may experience developmental delays, intellectual disability, and psychomotor retardation. Other common symptoms associated with West syndrome include crankiness, loss of appetite, changes in sleep patterns, regression, etc. The diagnosis of this disease is based on a review of the patient's medical history, clinical features, and neurological examination. An electroencephalogram (EEG) is also utilized among patients to detect patterns of electrical activity in the brain. The healthcare provider may further perform numerous diagnostic tests and procedures, including magnetic resonance imaging, computed tomography scan, urinalysis, cerebrospinal fluid test, blood workup, etc., to confirm a diagnosis and rule out other possible causes for underlying indications.
The rising cases of metabolic disorders, which can lead to a deficiency in brain energy, resulting in uncontrolled electrical abnormalities and brain damage, are primarily driving the West syndrome market. In addition to this, the increasing prevalence of various associated risk factors, such as brain injury, genetic defect, infection, brain malfunction, etc., is also acting as another significant growth-inducing factor. Furthermore, the widespread adoption of effective medications, including adrenocorticotropic hormone, prednisone, vigabatrin, pyridoxine, etc., to treat epileptic spasms and provide symptom relief in infants suffering from West syndrome, is creating a positive outlook for the market. Besides this, the emerging popularity of vagus nerve stimulation therapy, which helps to reduce seizures, promote mental development, and improve the quality of life of the patients, is also bolstering the market growth. Moreover, the escalating demand for a diet involving high fat, low carbohydrate with an adequate amount of protein and nutrients to control spasms, stabilize EEG, and enhance development and cognition, is expected to drive the West syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the West syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for West syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the West syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the West syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the West syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current West syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the West syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the West syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the West syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of West syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of West syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of West syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with West syndrome across the seven major markets?
What is the size of the West syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of West syndrome?
What will be the growth rate of patients across the seven major markets?
West Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for West syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the West syndrome market?
What are the key regulatory events related to the West syndrome market?
What is the structure of clinical trial landscape by status related to the West syndrome market?
What is the structure of clinical trial landscape by phase related to the West syndrome market?
What is the structure of clinical trial landscape by route of administration related to the West syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WEST SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 WEST SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WEST SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 WEST SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 WEST SYNDROME - UNMET NEEDS
10 WEST SYNDROME - KEY ENDPOINTS OF TREATMENT
11 WEST SYNDROME - MARKETED PRODUCTS
11.1 List of West Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Sabril (Vigabatrin) - sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 WEST SYNDROME - PIPELINE DRUGS
12.1 List of West Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 GWP42003P - GW Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AMZ002 - Amzell
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. WEST SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. WEST SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 WEST SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 West Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 West Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 West Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 West Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 West Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 West Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 West Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 West Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 West Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 West Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 West Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 West Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 West Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 West Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 West Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 West Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 West Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 West Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 West Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 West Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 West Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 West Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 West Syndrome - Access and Reimbursement Overview
16 WEST SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 WEST SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 WEST SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WEST SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 WEST SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WEST SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 WEST SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 WEST SYNDROME - UNMET NEEDS
10 WEST SYNDROME - KEY ENDPOINTS OF TREATMENT
11 WEST SYNDROME - MARKETED PRODUCTS
11.1 List of West Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Sabril (Vigabatrin) - sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 WEST SYNDROME - PIPELINE DRUGS
12.1 List of West Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 GWP42003P - GW Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AMZ002 - Amzell
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. WEST SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. WEST SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 WEST SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 West Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 West Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 West Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 West Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 West Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 West Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 West Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 West Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 West Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 West Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 West Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 West Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 West Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 West Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 West Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 West Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 West Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 West Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 West Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 West Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 West Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 West Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 West Syndrome - Access and Reimbursement Overview
16 WEST SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 WEST SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 WEST SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
